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Abstract
Introduction: Transient myeloproliferative disorder is a hematologic abnormality characterized by an uncontrolled
proliferation of myeloblasts in peripheral blood and bone marrow that primarily affects newborns and babies with
Down syndrome. Tumor lysis syndrome is rarely associated with transient myeloproliferative disorder.
Case presentation: Transient myeloproliferative disorder was diagnosed in a seven-day-old baby girl with Down
syndrome, who was referred to our department due to hyperleukocytosis. Our patient developed tumor lysis
syndrome, successfully treated with rasburicase, as a complication of transient myeloproliferative disorder resulting
from rapid degradation of myeloid blasts after initiation of effective chemotherapy.
Conclusions: Tumor lysis syndrome is rarely reported as a complication of transient myeloproliferative disorder. To
the best of our knowledge, this is the first case of a newborn with Down syndrome and transient
myeloproliferative disorder treated with rasburicase for developing tumor lysis syndrome.
Introduction
Transient myeloproliferative disorder (TMD) of Down
syndrome (DS), also known as transient abnormal mye-
lopoiesis, characteristically manifests in the first few
days of life with numerous circulating blast cells exceed-
ing the number of blast cells in the bone marrow and
with spontaneous or no resolution within a few weeks
[1-3]. Occasionally, however, TMD has preceded acute
megakaryoblastic leukemia (AML-M7) after a period of
remission lasting several months to years [4-6]. Tumor
lysis syndrome (TLS) is rarely reported after initiation of
effective chemotherapy as a complication of transient
myeloproliferative disorder [7].
In this report, we present a case of a baby with DS
and TMD who developed TLS successfully treated with
rasburicase.
Case presentation
A seven-day-old Caucasian baby girl with DS was
referred to our department due to hyperleukocytosis.
The baby was born by vaginal delivery at 39 weeks and
two days of gestation. Her Apgar scores were 8 and 9 at
one and five minutes, respectively. Her birth weight and
body length were 3420 g and 49 cm, respectively. Our
patient showed typical signs consistent with trisomy 21
confirmed by karyotype analysis (47, XX, +21). The sec-
ond day after birth, she presented to our facility with
reduced feeding intake. Peripheral blood test results
revealed a white blood cell (WBC) count of 70.8 × 10
9
cells/mm
3 with 70% of blasts. Due to hyperleukocytosis
our patient was referred to the Hematology Oncology
Unit of the Second Pediatric Department of Aristotle
University of Thessaloniki.O na d m i s s i o no u rp a t i e n t
had hepatosplenomegaly, abdominal distension, hypoto-
nia and dyspnea, probably due to hyperviscosity. Echo-
cardiography revealed a ventricular septal defect (VSD),
pericardial effusion and persistent pulmonary hyperten-
sion of newborn (PPHN). An ultrasound scan of the
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increased echo signaling of the liver. Biochemical data
revealed increasing levels of lactate dehydrogenase
(LDH) (2027IU/L), serum inorganic phosphorus (P) (6.0
m g / d L )a n du r i ca c i d( U A )( 4 . 2m g / d L ) .R e s u l t so f
blood gas analysis performed on admission were in the
normal ranges. The laboratory hematological, biochem-
istry and coagulation test results on admission are
shown in Table 1. Bone marrow aspiration revealed
hypercellular marrow with an excess of blasts. Antigeni-
tically, the blasts were negative for myeloperoxidase,
p o s i t i v ef o rC D 3 3 ,C D 3 4a n dC D 6 1 ,a n ds h o w e dw e a k
coexpression of CD7. The lymphoid and erythroid
populations exhibited no antigenic aberrations or atypi-
cality. On the basis of the blast cell immunophenotype,
the presentation suggested a diagnosis of TMD. Our
patient was put on antileukemic treatment with cyto-
sine-arabinoside (Ara-C) (1.5 mg/kg per day for eight
consecutive days) (day three) due to persistence of
hyperleukocytosis and deterioration of respiratory func-
tion (dyspnea, tachypnea). Parental written informed
consent was obtained prior to chemotherapy initiation.
Biochemistry test results after initiation of antineoplastic
treatment (day four) revealed increased levels of serum
potassium, serum inorganicp h o s p h o r u sa n dam a r g i n -
ally elevated level of uric acid (Table 1). Due to the fact
that our patient had hyperleukocytosis and elevated
LDH levels that meant a high tumor burden, we decided
to treat her for the increased risk of TLS development.
Therefore, she was put on rasburicase (0.2 mg/kg), fluid
therapy and forced diuresis treatment immediately.
Metabolic parameters were normalized seven days after
the initiation of rasburicase treatment (day 10). Labora-
tory hematological, biochemistry and coagulation test
values on day four (initiation of rasburicase) and 10
(end of rasburicase administration) are shown in Table
1. Peripheral blasts disappeared by day eight after the
initiation of Ara-C. Due to hepatosplenomegaly and
pericardial effusion, she developed mild respiratory dis-
tress without requiring ventilation. Our patient was dis-
charged at the age of six weeks with no further
complications and is currently well at the age of nine
months.
Discussion
We describe the case of a newborn with DS and TMD
who developed TLS that was successfully treated with
rasburicase. To the best of our knowledge this is the
first case of a newborn with DS and TMD treated with
rasburicase for preventing the occurrence of TLS.
Usually, transient leukocytosis associated with DS is
generally diagnosed in the first few weeks of life. TMD,
also known as transient leukemia, occurs in about 10%
of neonates with DS [6]. It is often accompanied by
hepatosplenomegaly, pericardial and pleural effusions,
hepatic disease, as in our patient and a pustular rash [6].
Although TMD resolves in the majority of DS babies,
20% to 30% subsequently go on to develop AML-M7,
usually within in the first 4 years of life [4,6]. AML
develops either by overt progression or after an apparent
remission of TMD with AML arising many months
later, presumably from a subcolony of persisting TMD
cells that acquire a selective advantage.
Most neonates with TMD do not need chemotherapy
as the clinical and laboratory abnormalities sponta-
neously resolve within three to six months after birth.
However, symptomatic babies with TMD, especially
those with high blast counts or liver dysfunction, may
benefit from low-dose cytosine arabinoside. Chemother-
apy is usually given at the treating physician’s discretion
and various groups have reported similar dosage sche-
dules and response. In the Pediatric Oncology Group
(POG) study 9481, 10 mg/m
2 per dose or 1.2 to 1.5 mg/
kg per dose was given subcutaneously or intravenously
by slow injection twice a day for seven days [8]. In the
AML-BFM study, 0.5 to 1.5 mg/kg was administered for
3 to 12 days [9]. As TMD blasts are highly sensitive to
cytarabine, there is generally a rapid response, character-
ized by the disappearance of peripheral blasts by day
seven of treatment. However this is not always the case,
especially in babies with severe liver disease associated
Table 1 Laboratory hematological, biochemistry and
coagulation test values from our patient on admission,
on day four (initiation of rasburicase) and day 10 (end of
rasburicase administration)
Day 1 Day 4 Day
10
White blood cell count (cells/μL) 70,800 43,500 4970
Hemoglobin (g/dL) 17.1 15.8 15.0
Hematocrit (%) 48.8 46.0 42.8
Platelets (cells/μL) 248,000 214,000 118,000
Total protein (g/dL) 4.90 4.74 5.16
Albumin (g/dL) 3.25 3.26 3.18
Lactate dehydrogenase (IU/L) 2027 2235 681
Urea (mg/dL) 20 18 15
Creatinine (mg/dL) 0.27 0.41 0.24
Sodium (mEq/L) 140 140 137
Potassium (mEq/L) 5.8 5.4 4.5
Phosphorus (mg/dL) 6.0 5.2 2.8
Calcium (mg/dL) 9.07 8.61 10.51
Uric acid (mg/dL) 4.2 4.0 0.8
Alanine aminotransferase (IU/L) 37 34 29
Aspartate aminotransferase (IU/L) 14 20 20
Prothrombin time (seconds) 13.8 12.0 12.2
Activated partial thromboplastin time
(seconds)
32.2 28.90 30.5
Fibrinogen (mg/dL) 279 253 266
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poor and overall there is a poor prognosis. Overall,
TMD has been reported to have a mortality rate of
approximately 20% [8,9].
TLS is a group of metabolic complications that can
occur after treatment for cancer, usually lymphomas
and leukemias, and sometimes even without treatment.
These metabolic complications include hyperkalemia,
hyperphosphatemia, hyperuricemia and hyperuricosuria,
hypocalcemia, and consequent acute uric acid nephropa-
thy and acute renal failure [7]. There are only few
reports of TLS associated with TMD [10,11]. Abe et al.
reported the case of a neonate with DS who developed
acute renal failure secondary to hypotension and TLS as
a complication of TMD. The patient was treated with
diuretics and pressor agents, but unfortunately died
[11]. Kato et al. reported the case of a baby with DS
who developed TLS as a result of TMD, successfully
treated with allopurinol and diuretics [10].
Conclusions
The clinical course of our patient indicates that TLS
may develop in cases with DS and TMD. Intensive sup-
portive and prophylactic therapy for preventing TLS
should be given in cases of TMD showing prominent
circulating blasts. To the best of our knowledge this is
the first case of a newborn with DS and TMD treated
with rasburicase for developing TLS.
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